Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 6.01% is 44% above its 5-year average of 4.16%, near the high end of its 5-year range (-1.14%–8.20%).
As of the fiscal period ended Wednesday, December 31, 2025. 6.09% below its 12-month average of 6.40%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
6.01%
RETURN ON EQUITY (ROE) AVG TTM
6.40%
RETURN ON EQUITY (ROE) AVG 3Y
5.73%
RETURN ON EQUITY (ROE) AVG 5Y
4.16%
RETURN ON EQUITY (ROE) AVG 10Y
4.62%
RETURN ON EQUITY (ROE) AVG 15Y
6.93%
RETURN ON EQUITY (ROE) AVG 20Y
8.83%
CURRENT VS TTM AVG
-6.09%
CURRENT VS 3Y AVG
+4.84%
CURRENT VS 5Y AVG
+44.47%
CURRENT VS 10Y AVG
+30.04%
CURRENT VS 15Y AVG
-13.33%
CURRENT VS 20Y AVG
-31.95%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-44.81%
vs the sector median at left
Zimmer Biomet Holdings, Inc.
Market Cap
$18.34B
Return on Equity (ROE)
6.01%
TTM Avg
6.40%
3Y Avg
5.73%
5Y Avg
4.16%
Market Cap
$16.97B
Return on Equity (ROE)
10.37%
TTM Avg
13.30%
3Y Avg
15.60%
5Y Avg
24.66%
Market Cap
$20.27B
Return on Equity (ROE)
-2.02%
TTM Avg
-13.64%
3Y Avg
-4.29%
5Y Avg
-4.38%
Market Cap
$15.96B
Return on Equity (ROE)
113.29%
TTM Avg
73.63%
3Y Avg
65.34%
5Y Avg
49.74%
Market Cap
$15.11B
Return on Equity (ROE)
28.82%
TTM Avg
23.51%
3Y Avg
17.50%
5Y Avg
13.68%
Market Cap
$21.90B
Return on Equity (ROE)
21.82%
TTM Avg
18.68%
3Y Avg
17.25%
5Y Avg
16.03%
Market Cap
$14.72B
Return on Equity (ROE)
-114.70%
TTM Avg
329.18%
3Y Avg
200.63%
5Y Avg
164.66%
Market Cap
$14.38B
Return on Equity (ROE)
2.86%
TTM Avg
4.70%
3Y Avg
4.67%
5Y Avg
11.22%
Market Cap
$22.34B
Return on Equity (ROE)
-46.61%
TTM Avg
-32.64%
3Y Avg
-13.90%
5Y Avg
0.25%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. (ZBH) | $18.34B | 6.01% | 6.40% | 5.73% | 4.16% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 10.37% | 13.30% | 15.60% | 24.66% |
| Viatris Inc. (VTRS)vs › | $20.27B | -2.02% | -13.64% | -4.29% | -4.38% |
| Medpace Holdings, Inc. (MEDP)vs › | $15.96B | 113.29% | 73.63% | 65.34% | 49.74% |
| Solventum Corporation (SOLV)vs › | $15.11B | 28.82% | 23.51% | 17.50% | 13.68% |
| United Therapeutics Corporation (UTHR)vs › | $21.90B | 21.82% | 18.68% | 17.25% | 16.03% |
| DaVita Inc. (DVA)vs › | $14.72B | -114.70% | 329.18% | 200.63% | 164.66% |
| The Cooper Companies, Inc. (COO)vs › | $14.38B | 2.86% | 4.70% | 4.67% | 11.22% |
| Moderna, Inc. (MRNA)vs › | $22.34B | -46.61% | -32.64% | -13.90% | 0.25% |
| Baxter International Inc. (BAX)vs › | $14.33B | -17.13% | -12.46% | -8.76% | -1.37% |
ROE
6.0%
ROA
3.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 5.55% |
| 2024-12-31 | 7.25% |
| 2023-12-31 | 8.20% |
| 2022-12-31 | 1.93% |
| 2021-12-31 | 3.17% |
| 2020-12-31 | -1.14% |
| 2019-12-31 | 9.13% |
| 2018-12-31 | -3.36% |
| 2017-12-31 | 15.46% |
| 2016-12-31 | 3.16% |
| 2015-12-31 | 1.49% |
| 2014-12-31 | 11.00% |
| 2013-12-31 | 12.08% |
| 2012-12-31 | 12.88% |
| 2011-12-31 | 13.81% |
| 2010-12-31 | 10.34% |
| 2009-12-31 | 12.72% |
| 2008-12-31 | 15.02% |
| 2007-12-31 | 14.19% |
| 2006-12-31 | 16.96% |
| 2005-12-31 | 15.64% |
| 2004-12-31 | 13.74% |
| 2003-12-31 | 11.02% |
| 2002-12-31 | 70.38% |
| 2001-12-31 | 190.34% |
| 2000-12-31 | 67.43% |
| 1999-12-31 | 38.36% |
| 1998-12-31 | 0.00% |
